HealthcareServices

Myelofibrosis (MF) Market Forecast 2026–2035: Data Trends and Industry Insights

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the myelofibrosis (mf) market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Myelofibrosis (MF) Market in 2026, and what figure is it projected to hit by 2030?

The myelofibrosis (mf) market has shown steady expansion in recent years. It is anticipated to grow from $1.55 billion in 2025 to $1.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.2%. The increase observed in the historic period is attributable to the limited availability of treatment options, a high prevalence of anemia among mf patients, a rise in autoimmune-related conditions, mounting diagnostic complexities, and a dependence on corticosteroid-based management.

The myelofibrosis (mf) market is projected to experience consistent expansion in the coming years. It is anticipated to reach $1.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.0%. This anticipated growth during the forecast period is driven by progress in JAK inhibitor development, the increasing embrace of precision medicine, heightened investment in hematology R&D, continuous advancements in stem-cell therapy, and the expanding availability of targeted oral treatments. Key trends for the forecast period encompass a rising uptake of JAK inhibitor-based therapies, a greater emphasis on combination treatment strategies, an increased focus on early diagnosis and screening initiatives, broadened research into stem-cell transplantation and regenerative care, and a more extensive application of supportive care to alleviate symptom load.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21226&type=smp

Which Drivers Are Affecting Market Participation In The Myelofibrosis (MF) Market?

The increasing need for targeted therapies is anticipated to drive the expansion of the myelofibrosis (MF) market in the future. This medical approach, known as targeted therapies, customizes treatments and healthcare choices according to a person’s unique genetic, environmental, and lifestyle attributes. The surge in demand for these therapies stems from progress in genomics, biotechnology, and data analytics, which facilitates more accurate, potent, and personalized treatment options. Myelofibrosis (MF) offers an essential foundation for creating targeted therapies by pinpointing crucial molecular pathways, including JAK-STAT signaling, thereby allowing for the formulation of precision treatments such as JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) to alleviate symptoms and impede disease progression. As an illustration, in May 2024, the American Cancer Society, a US-based non-profit organization, projected around 81,610 new kidney cancer cases (52,380 men and 29,230 women) in the United States for 2024, alongside an estimated 14,390 deaths (9,450 men and 4,940 women). Consequently, the escalating demand for targeted therapies is propelling the expansion of the myelofibrosis (MF) market.

What Segment Classifications Make Up The Myelofibrosis (MF) Market?

The myelofibrosis (mf) market covered in this report is segmented –

1) By Drug Type: Jak Inhibitor, Immunomodulators, Hydroxyurea, Other Drug Types

2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Jak Inhibitor: Ruxolitinib, Fedratinib, Momelotinib, Itacitinib

2) By Immunomodulators: Thalidomide, Lenalidomide, Pomalidomide

3) By Hydroxyurea: Oral Hydroxyurea, Injectable Hydroxyurea

4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs), Danazol, Monoclonal Antibodies, Chemotherapy Agents

Which Trends Are Expected To Influence The Myelofibrosis (MF) Market In The Upcoming Years?

Leading companies within the myelofibrosis (MF) market are concentrating on expanding targeted therapies, such as JAK1/JAK2 and ACVR1 inhibitors, to enhance treatment effectiveness, address disease progression, and improve patient outcomes in myelofibrosis (MF). JAK1/JAK2 inhibitors function by targeting the Janus kinase pathway to lessen inflammation and abnormal blood cell production in myelofibrosis, while ACVR1 inhibitors work by impeding activin receptor-like kinase 2 (ALK2) to regulate bone marrow fibrosis and disease advancement. For instance, in September 2023, GSK plc, a UK-based pharmaceutical company, obtained US Food and Drug Administration (FDA) approval for Ojjaara (momelotinib), indicated for the treatment of intermediate- or high-risk myelofibrosis. Its dual mechanism of action, targeting both JAK1/JAK2 and ACVR1, helps manage inflammatory pathways while also boosting hemoglobin levels, thereby reducing the need for transfusions. This approval not only broadens treatment choices but also establishes a new standard in MF management for patients struggling with anemia, a major unmet need in the disease landscape.

Which Leading Companies Dominate The Myelofibrosis (MF) Market Share?

Major companies operating in the myelofibrosis (mf) market are Pfizer Inc, Novartis AG, Incyte Corporation, CTI BioPharma Corp, Karyopharm Therapeutics Inc, Sierra Oncology Inc, Kartos Therapeutics Inc, NS Pharma Inc, Keros Therapeutics Inc, Pharmaxis Ltd, Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, AbbVie Inc, Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Taiga Biotechnologies Inc, Rigel Pharmaceuticals Inc, Imago BioSciences Inc, Samus Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/myelofibrosis-mf-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Myelofibrosis (MF) Market?

North America was the largest region in the myelofibrosis (MF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (mf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Myelofibrosis (MF) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21226&type=smp

Browse Through More Reports Similar to the Global Myelofibrosis (MF) Market 2026, By The Business Research Company

Idiopathic Pulmonary Fibrosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Multiple Myeloma Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795